Nothing said here yet.
to join the conversation.
| Equels Thomas KCEO & President | Buy | 31,675 | $5.1K | Fri, Oct 23 |
| Equels Thomas KCEO & President | Buy | 31,250 | $5.1K | Thu, Oct 22 |
| Equels Thomas KCEO & President | Buy | 24,000 | $5.0K | Thu, Sep 17 |
| Equels Thomas KCEO & President | Buy | 11,000 | $2.3K | Wed, Sep 16 |
| Equels Thomas KCEO & President | Buy | 22,000 | $4.9K | Tue, Sep 15 |
| Equels Thomas KCEO & President | Buy | 5,900 | $1.3K | Mon, Sep 14 |
Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program Recent biotech media features focus on Ampligen’s potential to address immune…
Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones Access it here OCALA, Fla., Sept.
Boulder County Wildfire Partners Commissioned the Artwork to Build Community Empowerment Around Wildfire Resilience as Part of Routine Home Maintenance BOULDER, Colo., Sept.
Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen’s potential to reshape the tumor microenvironment and enhance checkpoint inhibition
Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom
Annex Brands, Inc. Supports Local Entrepreneurs in Sustaining Essential Shipping and Office Services SAN DIEGO, Sept.
Patent covers synergistic use of Ampligen with pembrolizumab across cancer indications, including pancreatic, ovarian, colorectal, breast, lung and other cancers, reinforcing the potential breadth and long-term value of AIM’s oncology platform Patent covers…